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Piperidine ligands are described that provide the ®rst
examples of non-peptidic ligand structures for the cyclophilin
family of proteins. Crystal structures of two ligand complexes
are compared with the unliganded protein and show ligand-
induced changes in side-chain conformation and water
binding. A peptidylprolyl cis±trans-isomerase assay showed
the dissociation constants of the two ligands to be 320 and
25 mM. This study also provides the ®rst published data for
both enzymatic activity and three-dimensional structure for
any protein±ligand complex that binds with a high-millimolar
dissociation constant. The structures may be of relevance in
the ®eld of drug design, as they suggest starting points for the
design of larger tighter-binding analogues.
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1. Introduction
Cyclophilins belong to the family of peptidyprolyl-isomerase
(PPIase) enzymes that regulate protein folding and transport
(Galat & Metcalfe, 1995; Lilie et al., 1993). Cytosolic human
cyclophilin A (hCypA) is the most abundant form and is the
target for the immunosuppressant drug cyclosporin A, which
is used to prevent organ rejection after transplant operations
(Beveridge & Calne, 1995). Inhibition of various cyclophilin
isoforms may also be of potential therapeutic value in a
diverse range of disease areas. The discovery that inhibition of
cyclophilin prevents its incorporation into the HIV protein
coat suggests that families of inhibitors unrelated to the
immunosuppressant cyclosporins may have anti-HIV activity.
Parasitic nematodes require a variety of cyclophilins to
process collagen coat proteins at different stages in their life
cycle (Page et al., 1995) and the development of species-
speci®c cyclophilin inhibitors may also provide a route to
anti-parasitic drugs. The molecular structure of cyclophilin
provides a good template for the design of novel ligands, as the
active site seems to conserve its conformation when bound to
a variety of large and small peptide ligands (Taylor et al.,
1997).
There has been growing interest in the use of NMR (Meyer
& Peters, 2003; Glen & Allen, 2003) and protein X-ray crys-
tallography (Blundell et al., 2003) as tools for the discovery of
new ligands. These two structural approaches are particularly
good at identifying weakly binding ligands and complement
the high-throughput screening techniques which usually
restrict the search for novel ligands to those that bind with
low-micromolar dissociation constants (Bleicher et al., 2003).
Surveys of oral drug molecules (Davis & Teague, 1999) and
protein±ligand complex structures (Bohm & Klebe, 1996)
suggest that ligands that bind with better than micromolar
dissociation constants will typically consist of more than 20
non-H atoms and form some three hydrogen bonds. It is
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therefore of considerable interest to obtain more detailed
structural and binding information on the nature of weaker
protein±ligand interactions which may also provide a useful
starting point for drug-lead development.
There is a paucity of data in the literature on the inhibitory
and binding properties of weakly binding ligands, although
X-ray crystallographic studies of protein±solvent complexes
provide some structural insights (Ringe & Mattos, 1999).
Cross-linked protein crystals have been soaked in pure
solvents, including benzene, dimethylformamide and aceto-
nitrile. The re®ned X-ray structures provide a map of potential
ligand-binding sites (Allen et al., 1996). There are numerous
examples of other solvent molecules being sequestered in the
protein crystal lattice and the current Protein Data Bank
(Berman et al., 2000) has over 30 examples of proteins forming
complexes with dimethylsulfoxide, 20 examples of methanol
complexes and over 160 examples of glycerol complexes
formed during ¯ash-freezing experiments in which crystals are
soaked in solutions containing high concentrations of glycerol.
It is clear from these examples that when the concentration of
small-molecule solvent ligands is high (typically in the range
1.5±15 M), the law of mass action can act to form a complex
even if the dissociation constant is very large. In none of these
crystalline protein±ligand complexes is the dissociation
constant known. The work described in this paper provides
®rst examples of non-peptide ligands for cyclophilin and the
accompanying enzymatic data ®lls an important gap in our
understanding of how weak (millimolar) ligands bind.
2. Materials and methods
2.1. Enzymatic assay
PPIase activity is assessed using the -chymotrypsin-
coupled enzymatic assay (Kofron et al., 1991). -Chymotrypsin
selectively hydrolyses the C-terminal p-nitroanilide bond of
the substrate in the trans X-Pro conformer only. This hydro-
lysis releases the chromophore 4-nitroaniline, the accumula-
tion of which is recorded by measuring the absorbance at
400 nm as a function of time. The trans-peptide is cleaved
within the deadtime, so this cleavage does not contribute to
the total reaction time. The substrate (a stock solution of
100 mM) was dissolved in LiCl/tri¯uoroethanol (TFE). The
experiment took place at 277 K. Constant temperature was
maintained within the cuvette using a Peltier (PTP-1)
temperature-control unit. A mini magnetic stirring system
(Telemoduel, Variomag) was used to mix the solution in the
cuvette after the addition of the substrate. A Perkin±Elmer
UV/Vis Lambda 20 spectophotometer was used. The
substrate was N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide
(Bachem AG). hCypA solution was freshly prepared before
the experiment from frozen stock solution at the appropriate
concentration by dilution in 50 mM HEPES, 100 mM NaCl pH
8.0 (buffer A). In a typical experiment, 90 ml of 2.5±30 nM
hCypA was made up to 2520 ml with buffer A in a 3 ml glass
cuvette. The cuvette was then preincubated for 30 min on ice.
Immediately before the assay, 300 ml of chymotrypsin (Sigma)
solution (50 mg mlÿ1 in 10 mM HCl) was added, followed by
90 ml of a 3.7 mM stock solution of Suc-Ala-Ala-Pro-PNA in
LiCl (470 mM)/TFE. The reaction progress was monitored by
the absorbance change at 400 nm that accompanies the
hydrolysis of the amide bond and the release of 4-nitroaniline
product.
2.2. Crystallization and structure determination
Recombinant hCypA was concentrated to 14 mg mlÿ1 in
20 mM HEPES, 100 mM NaCl, 0.02%(w/v) NaN3. Crystals of
hCypA were grown by vapour diffusion at 290 K by the
hanging-drop method. The precipitating solution in the well
consisted of 100 mM Tris±HCl pH 8.0, 22%(w/v) PEG 8000,
5%(v/v) DMSO, 0.02% NaN3. The initial 8 ml drop consisted
of 50 mM Tris±HCl pH 8.0, 11%(w/v) PEG 8000, 2.5%(v/v)
DMSO, 0.02% NaN3, 0.4 mM hCypA.
The ligand was introduced into the crystal (0.2  0.1 
0.025 mm) using a stepwise-soaking procedure in which the
DMSO concentration was gradually reduced and the ligand
concentration was gradually increased. This procedure was
required to prevent crystal damage and also to prevent
competition by DMSO binding at the active site. In the ®rst
step, a single crystal of hCypA was soaked in a precipitating
solution containing 20 mM ethyl-1-piperidine glyoxylate
(ETPIPG) and a reduced (4%) concentration of DMSO. After
1 h, the crystal was transferred to a fresh soaking solution
containing 40 mM ligand and 3% DMSO. The crystal was
transferred a total of six times over a period of 6 h. The ®nal
soak was for 2.5 h in a solution containing no DMSO and
180 mM ETPIPG. The same stepwise-soaking procedure was
followed for a crystal (0.3  0.15  0.05 mm) soaked in
1-acetyl-3-methylpiperidine (ACMPIP). The initial ligand
concentration of 50 mM was again increased over six steps to a
®nal concentration of 300 mM.
Flash-freezing of the crystal in liquid nitrogen was carried
out after soaking in a cryoprotectant solution consisting of
100 mM Tris±HCl pH 8.0, 22%(w/v) PEG 8000, 0.02% NaN3,
180 mM ligand and 26% glycerol. Data were collected using a
Nonius rotating-anode generator. The resolution of the data
was improved when data from the same crystal were collected
at Daresbury SRS ( = 1.488 AÊ ). Data sets were processed
with DENZO and scaled with SCALEPACK.
3. Results and discussion
3.1. Ligand design and ligand selection
The largest family of cyclophilin inhibitors are related to the
cyclic peptide cyclosporine A (Kallen et al., 1998) and a
number of weaker proline-containing oligopeptides also show
inhibition (Kallen & Walkinshaw, 1992; Ke et al., 1993).
Recently, families of new non-peptide inhibitors have been
synthesized (Wu et al., 2003). In this work, we used the simi-
larity search available in ISIS to identify molecules similar to
the cis-proline found in a number of peptide ligands (Taylor et
al., 1997). One selection requirement was the presence of a
hydrogen-bond donor to mimic the carbonyl O atom of the
peptidylprolyl bond (Fig. 1). A hydrogen bond between this
carbonyl O atom and the backbone N atom of Asn102 is
conserved in all peptide±cyclophilin structures. The second
feature was the requirement of a hydrophobic group to mimic
the valine side chain of cyclosporin or the proline side chain of
the peptide ligands. Two piperidine derivatives (Fig. 1) were
selected according to these criteria.
The two published cyclophilin-binding assays make use of
either ¯uorescence spectroscopy (Husi & Zurini, 1994) or
enzymatic inhibition (Kofron et al., 1991). The assay is based
on the fact that chymotrypsin can only cleave the prolyl amide
bond when in the trans coformation. Cyclophilins speed up the
production of the trans conformer. The inhibitory activity of
ACMPIP and ETPIPG has Ki values of 320 and 25 mM,
respectively.
3.2. Crystal structures of native cyclophilin and two
cyclophilin±ligand complexes
In order to make an accurate comparison of the structural
effects of ligand binding, a high-resolution low-temperature
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Table 1
Crystallographic data for native hCypA and complexes.
ETPIPG ACMPIP Native
Unit-cell parameters (AÊ )
a 36.26 36.08 36.17
b 54.54 54.31 56.56
c 71.1 70.97 70.28
Space group P212121 P212121 P212121
Resolution (AÊ ) 1.65 1.8 1.7
Temperature (K) 100 100 100
No. collected re¯ections 184971 103411 126301
Unique re¯ections 17641 13305 16375
Completeness of data (%) 90.2 98.7 99.5
Redundancy (%) 10.5 7.77 7.71
Rmerge² (%) 4.0 5.0 5.1
Final R factor (all data) (%) 18.5 17.8 17.4
Free R factor (10% of data) (%) 22.5 23.1 21.9
Total non-H atoms 1535 1564 1458
Solvent sites 243 193 192
R.m.s.d. from ideality
Bond lengths (AÊ ) 0.007 0.007 0.007
Bond angles () 1.302 1.252 1.321
Mean temperature factors (AÊ 2)
Protein atoms 15.92 14.43 12.82
Ligand atoms (AÊ 2) 20.95 (ALT1, 65%),
21.42 (ALT2, 35%)
25.09
Water molecules (AÊ 2) 35.26 31.17 30.72
² Rmerge = (
P jI ÿ hIij=P jIj), where I is the observed intensity and hIi is the average
intensity from observations of symmetry-related re¯ections.
Table 2
Non-bonded contacts and hydrogen bonds in the active site for native
hCypA, hCypA±ACMPIP and hCypA±ETPIPG.
hCypA
atom Native
Distance
(AÊ ) ETPIPG
Distance
(AÊ ) ACMPIP
Distance
(AÊ )
Phe60 CZ C1 (ALT2) 3.21 C4 3.49
Phe60 CE1 C1 (ALT2) 3.69 C9 3.54
Leu122 CD2 W121 3.71
Arg55 NH2 C5 (ALT2) 3.77 C9 3.67
(ALT2) Arg55
NH2
C2 3.04
Arg55 NH2 C4 (ALT2) 3.91
Arg55 NH1 C1 (ALT2) 3.05
Arg55 NH2 W208 2.58 O4 (ALT1) 3.44
Arg55 NE W208 3.64
Arg55 NH2 N1 (ALT2) 3.73
Arg55 CD W208 3.74
Arg55 CDZ W208 3.12
Phe113 CE1 W106 3.71 C3 (ALT2) 3.48 C5 3.56
Phe113 CD1 W106 3.32 C3 (ALT2) 3.49 C5 3.64
Phe113 CD1 C8 (ALT1) 3.77 C6 3.61
C2 (ALT2) 3.79
Met61 CE W106 3.08
Gln63 OE1 W208 3.13 N1 (ALT2) 3.73
Gln63 OE1 C7 (ALT1) 3.70
Gln63 OE1 W106 2.92 O3 (ALT2) 3.73
Gln63 OE1 O4 (ALT1) 3.70
Gln63 OE1 C8 (ALT1) 3.45
Gln63 CD W106 3.55
Gln63 NE2 W107 3.21 O2 (ALT1) 3.57
O3 (ALT2) 3.53
Asn102 N W105 2.90 C6 (ALT2) 3.77 O2 2.77
Asn102 N O2 (ALT2) 2.71
O3 (ALT1) 3.07
Asn102 O O2 (ALT1) 3.78 O2 3.29
Asn102 O C2 (ALT1) 3.26 C8 3.27
C8 (ALT2) 3.67
Asn102 O W105 3.10 N1 (ALT1) 3.45
O4 (ALT2) 3.36
Asn102 O W107 3.68 C3 (ALT1) 3.62
C7 (ALT2) 3.21
C6 (ALT2) 3.77
Asn102 O C6 (ALT1) 3.56
Asn102 O W198 3.69 O3 (ALT1) 3.68
O2 (ALT2) 3.44
His126 CE1 W105 3.35 C3 (ALT2) 3.74 C7 3.60
O3 (ALT1) 3.13
His126 CE1 O2 (ALT2) 3.26
His126 CE1 C5 (ALT1) 3.71 O2 3.07
His126 CE1 C4 (ALT1) 3.67
His126 CE1 C7 (ALT1) 3.76
His126 CE1 C6 (ALT2) 3.46
His126 CE1 W121 3.65 N1 (ALT2) 3.69
His126 NE2 W121 2.86 C5 (ALT1) 3.75
His126 NE2 C4 (ALT1) 3.75
His126 ND1 O3 (ALT1) 3.68
O2 (ALT2) 3.73
Ala101 C W105 3.60 O3 (ALT1) 3.57 O2 3.41
Ala101 C O2 (ALT2) 3.22
Ala101 CA W105 3.36 O3 (ALT1) 3.11 O2 3.14
Ala101 CA O2 (ALT2) 2.84
Ala101 CB W105 3.38 O3 (ALT1) 3.18 O2 3.30
Ala101 CB W106 3.55 O2 (ALT2) 2.92
Solvent
W93 W109 2.89
W105 W106 2.84
W105 W107 3.14
W105 W198 2.97
W106 W208 3.66
W107 W208 3.74
W109 O4 (ALT1) 3.20
W121 W198 3.32
W146 W198 3.60
Figure 1
Formulae of the two ligands ACMPIP and ETPIPG, showing the
similarity to cis-proline.
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structure determination of native hCypA cyclophilin was
carried out (Table 1). The low-temperature structure
presented here enabled the location of native structure of four
of the active-site water molecules W198, W106, W121 and
Figure 2
(a) 1Fo ÿ 1Fc unbiased electron-density map for hCypA±ACMPIP
contoured in red at 2.5. The map was calculated using data to 1.8 AÊ with
phases from the partially re®ned `native' hCypA structure which had not
been contaminated with a ligand model. A stick representation of
ACMPIP in its ®nal re®ned orientation is shown for reference. (b) Final
2Foÿ 1Fc electron-density map for hCypA±ACMPIP contoured in red at
1 calculated using phases from all atoms including waters and ligand.
The orientation is selected to show the alternative conformations of
Arg55 in proximity to the ACMPIP ligand.
Figure 3
(a) Overlay of native hCypA (cyan) with hCypA±ACMPIP (atom-type
colours). Close contacts between the ACMPIP ligand with surrounding
atoms are shown. ACMPIP makes one hydrogen bond to Asn102 N
(2.8 AÊ ). The most hydrophobic part of the ACMPIP molecule (the
methylpiperidine ring) ®ts into the hydrophobic pocket. van der Waals
contacts are made from the ligand to the side chains of six amino acids
(Arg55, Phe 60, Met61, Gln63, Phe113 and His126). (b) Overlay of native
hCypA (cyan) with the hCypA±ETPIPG in both binding modes (ALT2,
green; ALT1, purple). The main difference between the native protein
structure and the structure with ETPIPG in the binding site is the
movement of the side chain of Met61. The overall backbone conforma-
tions of the three structures are very similar. An r.m.s. ®t of all protein
atoms except residues 1±4, 67±76 and 162±165 between native and the
ACMPIP complex is 0.286 AÊ and that between the ACMPIP and
ETPIPG complexes is 0.367 AÊ .
W109 (Table 2) which were not observed in an earlier room-
temperature structure (Ke et al., 1991).
A hCypA±ACMPIP complex was prepared by soaking a
crystal of native hCypA in a saturated solution of ACMPIP; an
initial difference Fourier map showed clear electron density in
the active site (Fig. 2) consistent with the ligand. The binding
mode of ACMPIP mimics the binding of cis-proline ligands in
a number of X-ray structures (Zhao & Ke, 1996; Kallen &
Walkinshaw, 1992; Taylor et al., 1997). A hydrogen bond
between the amide carbonyl O atom of the ligand and the
amide N atom of Asn102 (O  N = 2.77 AÊ ) provides the
key recognition feature (Fig. 3a; Table 2). This hydrogen
bond can only be formed by proline derivatives in the cis
conformation. The well de®ned hydrophobic pocket in the
active site is bounded by Phe60, Met61, Phe113 and Leu122
and is ®lled by the piperidine ring as predicted. Differences
between the native protein structure and the structure with
ACMPIP in the binding site are the movement of the side
chain of Met61 observed in all other small ligand structures
with hCypA, the replacement of ®ve water molecules (W105,
W106, W198, W109 and W208) by ACMPIP and the
signi®cantly different conformation of the Arg55 side chain
(Fig. 3a).
The hCypA±ETPIPG complex was prepared by soaking a
hCypA crystal in a saturated solution of ETPIPG. The
complex with ETPIPG is found to adopt two different but
overlapping orientations in the active site (Fig. 4). Different
trial occupancies for the two ligand orientations were tested
and individual atom B factors for each ligand were re®ned.
Occupancies of 0.35 and 0.65 gave comparable B factors for
the atoms in each ligand (Table 1). The lower (35%) occu-
pancy orientation of the ligand (ALT2) is similar to the
binding mode adopted by ACMPIP, with the piperidine ring
®tting in the hydrophobic pocket lined by Phe113, Met61 and
Phe60 (Figs. 3b and 5). The hydrogen bond between Asn102 N
and the carbonyl O atom O2 (N  O = 2.71 AÊ ) is also
conserved. The alternative orientation of the ligand (ALT1)
has an occupancy of 65% and sits in a rotated orientation in
the binding pocket such that that the ethyl group now occupies
the hydrophobic pocket and the piperidine group is essentially
exposed to solvent. The approximate twofold symmetry of the
ETPIPG ligand, however, means that the binding sites in the
active-site pocket are ®lled by pseudo-symmetry-related
atoms (Figs. 3b and 5). The ALT1 mode allows all three O
atoms in the glyoxylate group to form potential hydrogen
bonds with Asn102, Arg55 and Gln63. There is also a close
and favourable contact between the backbone carbonyl O
atom of Asn102 and the amide N atom of the piperidine ring
(Fig. 5; Table 2). These additional electrostatic interactions are
presumably at the expense of moving the hydrophobic
piperidine ring out of the hydrophobic pocket. The confor-
mations of the ethylglyoxylate molecule is similar in both of its
binding modes and both maintain an expected O CÐC O
torsion angle of 90 for the ± carbonyl O atoms. The only
signi®cant difference between the binding pockets of the two
structures is in the conformation of the side chain of Arg55,
which is pushed away from the binding site in the ACMPIP
structure but is involved in ligand binding in the ETPIPG
structure.
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Figure 4
(a) 1Fo ÿ 1Fc unbiased electron-density map for hCypA±ETPIPG
contoured in red at 2.5. The map was calculated using data to 1.6 AÊ with
phases from the partially re®ned `native' hCypA structure which had not
been contaminated with a ligand model. A stick representation of the two
disordered ETPIPG molecules in their ®nal re®ned orientations are
overlaid: ALT1 (65% occupancy; C atoms purple) and ALT2 (35%
occupancy; C atoms green). (b) Difference electron-density map
(2Fo ÿ 1Fc) for the re®ned ETPIPG±hCypA complex contoured at 1.
Both water molecules and ligand were included in the phase calculation.
The two orientations of ETPIPG are shown: ALT1 (65% occupancy; C
atoms purple) and ALT2 (35% occupancy; C atoms green).
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3.3. Factors affecting the strength of protein±ligand
interactions
A number of attempts have been made to estimate ligand-
binding strength as a linear sum of factors, including van der
Waals contacts, hydrogen bonds, rotational and translational
entropy changes (Klebe & Bohm, 1997). For families of
related ligands binding to the same enzyme, it is possible to
obtain good correlations between calculated and measured
binding constants (Verkhivker et al., 1995; Muegge et al., 1999;
Goodsell et al., 1996; Knegtel et al., 1999; Davies et al., 1999).
The combined structural and enzymatic data available is
relatively sparse, with examples from about 20 different
enzyme±ligand complexes (Bohm, 1994). The complex of
cancanavalin A with methylmannoside (Naismith et al., 1994),
which has an experimental dissociation constant of 0.95 mM
(corresponding to a binding energy of ÿ62.7 kJ molÿ1), is one
of the weakest binding complexes to have been jointly char-
acterized unambiguously by X-ray crystallography and
binding studies. The cyclophilin structures presented here are
orders of magnitude weaker than this: the Ki values of
ACMPIP and ETPIPG are 320 and 25 mM, respectively,
corresponding to binding energies of ÿ2.4 and ÿ9 kJ molÿ1.
The buried surface of the ligand provides some measure of
the van der Waals interaction energy. The buried surface areas
of ACMPIP and ETPIPG are 205 and 189 (ALT1) and 196 AÊ 2
(ALT2), respectively. Estimates of the surface-energy contri-
butions to binding energy vary between about ÿ0.2 and
ÿ0.5 kJ molÿ1 AÊ ÿ2 (Bohm, 1998; Burkhard et al., 2000). This
gives binding-energy estimates of between 40 and
100 kJ molÿ1 for both ligands, although the ACMPIP ligand
has a marginally higher solvent-excluded binding surface but
binds signi®cantly more weakly. For both ligands the calcu-
lated enthalpic terms are signi®cantly greater than the
observed binding strengths, which suggests that a number of
unfavourable energy effects must also play a role.
One major energy cost for ligand binding is caused by the
break-up and displacement of the water structure in the active
site. ACMPIP displaces ®ve water molecules and ETPIPG
displaces six water molecules from the active site (Figs. 3a and
4b). In the native structure, W105 is hydrogen bonded to
Asn102 and in both cyclosporin A complexes and the piper-
idine family of cyclophilin ligands, W105 is mimicked by a
carbonyl O atom. One difference between the binding of the
two ligands is the number of (weak) but direct hydrogen bonds
between the ligand and the protein (Table 2). In ACMPIP and
ETPIPG there is one direct hydrogen bond to Asn102 N and
in both binding modes of the ETPIPG there are an additional
one or two weak hydrogen bonds. Hydrogen bonds are esti-
mated to contribute about ÿ5 kJ molÿ1 (Klebe & Bohm,
1997) to the binding energy. On binding piperidyl ligands to
cyclophilin, one good hydrogen bond is made, but networks of
more than 11 water±protein and water±water hydrogen bonds
have been lost in the two complexes. There are also additional
ripple effects at the edge of the active site where more distant
hydrogen-bonding water partners are perturbed by side-chain
movements.
Induced conformational change in protein side chains may
also reduce the energy of binding. Three amino-acid side
chains in proximity to the active site (Met61, Arg55 and
Gln63) show signi®cantly different conformations in the three
structures (Figs. 3a and 3b). The Met61 side chain adopts a
different conformation in both structures, with a change in 3
of about 120. The catalytically important residue Arg55 forms
hydrogen bonds to most peptide ligands (Taylor et al., 1997).
There is no hydrogen-bonding possibility with ACMPIP and
the guanidinium group is twofold disordered in this complex.
ETPIPG does not have the additional bulk of the C3 methyl
group on the piperidine ring, which leaves enough room for
the Arg55 side chain to adopt a single conformation similar to
that found in the native hCypA structure. It seems likely that
Figure 5
Diagrammatic representation of the major ligand±protein interactions. Hydrogen bonds are shown as dotted lines. The hydrophobic pocket is primarily
bounded by the side chains of Phe113 and Phe60, which are shown as green ovals.
the repulsion between the methyl group of ACMPIP and
Arg55 accounts for a major difference between the Ki values
of the two piperidyl ligands. The entropic contribution to
binding energy from the twofold-disordered ETPIPG struc-
ture is dif®cult to assess. It has been observed previously that
ligands can frequently bind in different modes (Mattos et al.,
1994).
3.4. The role of weakly binding pro-ligands in the
development of pharmaceutical leads
The success of `SAR by NMR' in designing tight-binding
FK506 binding protein ligands (Shuker et al., 1996) highlights
the importance of making use of weakly binding pro-ligands.
The major problem in studying the interaction of such weakly
binding ligands is being able to reach a suf®ciently high ligand
concentration. NMR studies of lysozyme have been carried
out in high concentrations (1±13 M) of organic solvents
including DMSO, methanol and acetonitrile (Liepinsh &
Otting, 1997). X-ray studies of elastase crystals soaked in
acetonitrile have also been used to map possible binding sites
(Allen et al., 1996).
The micromolar criterion used in high-throughput
screening searches for new ligands requires ligands to have a
dissociation energy of less than ÿ33.6 kJ molÿ1. It is unlikely
that small ligands will bind with this energy, principally
because of the competition with water. Both the entropy and
enthalpy of a small ligand are comparable to those of bound
water. Thus, the combined effects of a small binding-surface
area and the competition with water normally require organic
ligands to be of a molecular weight greater than 300 Da for
micromolar binding. Small-molecule drugs typically have
molecular weights of between 300 and 700 Da.
The structures presented here show that it is possible to
obtain ordered X-ray structures for weakly binding low-
molecular-weight ligands using conventional crystal-soaking
methods. Once a pharmacophore can be accurately located in
the binding pocket of an enzyme, the structure can be used as
template for the design of larger (tighter binding) chemical
derivatives.
We thank Novartis AG for supporting this work, the
CCLRC for synchrotron facilities and the Edinburgh Protein
Interaction Centre (EPIC) for use of equipment.
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